Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

CDK4 & 6 inhibitors have enhanced the effectiveness of endocrine therapy (ET) in patients with advanced breast cancer (ABC). This paper presents exploratory analyses examining patient and disease characteristics that may inform in whom and when abemaciclib should be initiated. MONARCH 2 and 3 en...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Leo, Angelo, O’Shaughnessy, Joyce, Sledge, George W., Martin, Miguel, Lin, Yong, Frenzel, Martin, Hardebeck, Molly C., Smith, Ian C., Llombart-Cussac, Antonio, Goetz, Matthew P., Johnston, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299082/
https://www.ncbi.nlm.nih.gov/pubmed/30588487
http://dx.doi.org/10.1038/s41523-018-0094-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299082/
https://www.ncbi.nlm.nih.gov/pubmed/30588487
http://dx.doi.org/10.1038/s41523-018-0094-2

Ejemplares similares